Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Zydus Lifesciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 5,011 | 5,140 | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 |
| Expenses + | 3,755 | 3,634 | 3,223 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 |
| Operating Profit | 1,256 | 1,505 | 1,146 | 1,102 | 1,630 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 |
| OPM % | 25% | 29% | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% |
| Other Income + | -566 | 21 | 53 | 60 | 160 | 63 | 68 | 57 | -139 | 155 | 75 | 26 | -263 |
| Interest | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 |
| Depreciation | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 |
| Profit before tax | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 |
| Tax % | 28% | 16% | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% |
| Net Profit + | 358 | 1,134 | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 |
| EPS in Rs | 2.93 | 10.74 | 7.91 | 7.80 | 11.75 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 |
Financials of Zydus Lifesciences Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 |
| Expenses + | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,758 | 11,923 | 13,378 | 14,163 | 16,183 | 18,673 |
| Operating Profit | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,344 | 3,342 | 3,860 | 5,384 | 7,058 | 8,475 |
| OPM % | 20% | 25% | 20% | 24% | 23% | 20% | 22% | 22% | 22% | 28% | 30% | 31% |
| Other Income + | 45 | 112 | 127 | 111 | 183 | -264 | -171 | 2,581 | -422 | 293 | 50 | -7 |
| Interest | 68 | 53 | 45 | 91 | 194 | 342 | 164 | 127 | 130 | 81 | 166 | 439 |
| Depreciation | 287 | 292 | 373 | 539 | 599 | 696 | 725 | 713 | 723 | 764 | 916 | 1,408 |
| Profit before tax | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,285 | 5,084 | 2,585 | 4,832 | 6,027 | 6,621 |
| Tax % | 18% | 8% | 8% | 24% | 22% | 21% | 6% | 10% | 23% | 20% | 23% | 24% |
| Net Profit + | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 |
| EPS in Rs | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 | 50.09 |
| Dividend Payout % | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% | 8% | 24% | 2% |
Financials of Zydus Lifesciences Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 |
| Reserves | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,852 | 27,011 |
| Borrowings + | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,584 | 4,221 | 1,195 | 804 | 3,213 | 12,496 |
| Other Liabilities + | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,189 | 6,421 | 6,851 | 8,201 | 9,523 | 12,799 |
| Total Liabilities | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 52,407 |
| Fixed Assets + | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,253 | 11,521 | 12,368 | 13,134 | 26,639 |
| CWIP | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 661 | 1,201 | 2,423 | 2,692 | 1,166 |
| Investments | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,220 | 6,408 | 7,540 |
| Other Assets + | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 12,822 | 14,456 | 17,062 |
| Total Assets | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 52,407 |
Financials of Zydus Lifesciences Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,505 | 3,293 | 2,104 | 2,689 | 3,228 | 6,777 | 2,117 |
| Cash from Investing Activity + | -465 | -860 | -2,872 | -974 | -3,977 | -1,012 | -835 | 1,137 | 1,178 | -1,492 | -8,377 | -8,296 |
| Cash from Financing Activity + | -351 | -935 | 2,316 | 52 | 1,885 | -1,094 | -2,549 | -868 | -4,400 | -1,810 | 2,014 | 5,807 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 2,373 | -534 | -75 | 414 | -373 |
| Free Cash Flow | 498 | 936 | -1,623 | -116 | 236 | 1,617 | 2,446 | 1,050 | 1,697 | 2,345 | 5,116 | -530 |
| CFO/OP | 79% | 109% | 81% | 54% | 65% | 100% | 109% | 83% | 85% | 84% | 122% | 44% |
Financials of Zydus Lifesciences Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 67 | 68 | 89 | 98 | 110 | 94 | 76 | 80 | 94 | 97 | 63 | 73 |
| Inventory Days | 175 | 158 | 193 | 211 | 208 | 207 | 227 | 245 | 197 | 202 | 227 | 282 |
| Days Payable | 125 | 154 | 165 | 167 | 149 | 151 | 155 | 141 | 123 | 125 | 133 | 142 |
| Cash Conversion Cycle | 118 | 71 | 116 | 142 | 169 | 150 | 148 | 184 | 168 | 175 | 158 | 212 |
| Working Capital Days | 6 | -1 | -34 | 17 | 10 | -19 | -6 | 19 | 70 | 88 | 3 | 37 |
| ROCE % | 23% | 28% | 16% | 18% | 15% | 11% | 14% | 13% | 15% | 22% | 24% | 21% |